MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

• Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo -

• Panorama builds on positive Phase 2b study results presented at the American Psychiatric Association’s Annual Meeting in May 2024 and will be conducted at sites in the US and Europe -

• Topline data from the 12-week double-blind period anticipated in the second half of 2026 -

https://www.businesswire.com/news/home/20250127889062/en/MindMed-Announces-First-Patient-Dosed-in-Panorama-the-Second-Pivotal-Phase-3-Study-of-MM120-in-Generalized-Anxiety-Disorder?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark